A considerable number of patients with chronic inflammatory bowel diseases (IBD)
are required to manage extensive polypharmaceutical regimes, which significantly
elevates the risk of drug–drug interactions. Also, the disease’s impact often leads to
the consumption of additional self-medication by the patients such as naturopathic
remedies to alleviate disease-induced suffering and nutritional supplements to
compensate for malabsorption syndromes inherent to the condition. There is
a well-established consensus that polymedication coupled with unregulated
supplementary intake can jeopardize the safety of drug therapy. Despite this,
pharmaceutical co-supervision—proven to mitigate adverse drug events and
enhance patient adherence to treatment—is generally lacking in routine clinical
settings. Furthermore, the assessment of individual therapy adherence, a crucial
predictive factor for therapeutic outcomes, is frequently suboptimal. In response
to these issues, this study implemented an interdisciplinary approach wherein
a team comprising medical and pharmaceutical professionals conducted a
comprehensive survey coupled with a medication review for patients attending
an IBD outpatient clinic. Employing an IBD-specific questionnaire alongside
the patients’ documented medication regimens enabled the identification and
subsequent discussion of current therapeutic concerns and potential medicationrelated
risks during follow-up consultations. This intervention aimed to bolster
individual patient satisfaction and enhance medication safety, ultimately fostering
sustained success in IBD management.